Priority Research Centre for Asthma and Respiratory Diseases, University of Newcastle, Newcastle, New South Wales, Australia Department of Respiratory and Sleep Medicine, John Hunter Hospital, New Lambton Heights, New South Wales, Australia.
Thorax. 2015 Jul;70(7):683-91. doi: 10.1136/thoraxjnl-2014-206740. Epub 2015 May 6.
The overlap between asthma and COPD is increasingly recognised. This review examines the new insights, treatment and remaining knowledge gaps for asthma-COPD overlap.
A systematic literature review of cluster analyses of asthma and COPD was performed. Articles from 2009 to the present dealing with prevalence, morbidity and treatment of asthma-COPD overlap were identified and reviewed.
Asthma-COPD overlap was consistently recognised in studies using a variety of different study designs and sampling. The prevalence was approximately 20% in patients with obstructive airways diseases. Asthma-COPD overlap was associated with increased morbidity and possibly an increased mortality and comorbidity. There was evidence of a heterogeneous pattern of airway inflammation that included eosinophilic (in adult asthma), neutrophilic or mixed patterns (in severe asthma and COPD). Systemic inflammation was present in asthma-COPD overlap and resembled that of COPD. Within asthma-COPD overlap, there is evidence of different subgroups, and recognition using bronchodilator responsiveness has not been successful. Guidelines generally recommend a serial approach to assessment, with treatment recommendations dominated by an asthma paradigm. Research is needed into key clinical features that impact outcome, mechanisms and treatment approaches in asthma-COPD overlap. Identifying and treating disease components by multidimensional assessment shows promise.
Asthma-COPD overlap has drawn attention to the significant heterogeneity that exists within obstructive airway diseases. It should be replaced by novel approaches that identify and manage the components of this heterogeneity, such as multidimensional assessment and treatment. Future research is needed to test these novel and personalised approaches.
哮喘和 COPD 之间的重叠现象越来越受到重视。本综述探讨了哮喘-COPD 重叠的新见解、治疗方法和尚存的知识空白。
对哮喘和 COPD 的聚类分析进行了系统的文献回顾。检索了 2009 年至今涉及哮喘-COPD 重叠的患病率、发病率和治疗的文章,并进行了综述。
在使用各种不同研究设计和抽样方法的研究中,均一致地认识到了哮喘-COPD 重叠现象。在患有气道阻塞性疾病的患者中,其患病率约为 20%。哮喘-COPD 重叠与发病率增加有关,可能与死亡率和合并症增加有关。气道炎症存在异质性模式,包括嗜酸性粒细胞(成人哮喘中)、中性粒细胞或混合模式(严重哮喘和 COPD 中)。哮喘-COPD 重叠存在系统性炎症,类似于 COPD。在哮喘-COPD 重叠中,有证据表明存在不同的亚组,而使用支气管扩张剂反应性进行识别并不成功。指南通常建议采用连续评估方法,治疗建议主要以哮喘范式为主。需要研究影响结局、机制和哮喘-COPD 重叠治疗方法的关键临床特征。通过多维评估识别和治疗疾病成分具有一定的前景。
哮喘-COPD 重叠现象引起了人们对气道阻塞性疾病中存在的显著异质性的关注。应该用新的方法来取代它,这些方法可以识别和管理这种异质性的组成部分,例如多维评估和治疗。需要进一步研究来检验这些新的和个性化的方法。